Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefpodoxime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 0.98 |
| ▸ | HTR2C | P28335 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 3/20 | 0.85 |
| ▸ | PPARG | P37231 | 2/20 | 0.85 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.85 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.85 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.85 |
| ▸ | ALB | P02768 | 1/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.73 |
| ▸ | APEX1 | P27695 | 3/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefpodoxime SCHEMBL27459257 | 1.00 | NR1I2 (0.98) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL3014527 | 1.00 | NR1I2 (0.98) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL6688590 | 0.99 | NR1I2 (1.00) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL16072818 | 0.99 | NR1I2 (1.00) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL2015784 | 0.99 | NR1I2 (1.00) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL69122 | 0.99 | NR1I2 (1.00) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL27072 | 0.99 | NR1I2 (1.00) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL13189562 | 0.99 | NR1I2 (1.00) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL2015780 | 0.99 | NR1I2 (1.00) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefpodoxime SCHEMBL5265715 | 0.98 | NR1I2 (0.98) | NR1I2HTR2CMAPTPPARGSLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110746373-A | Method for preparing 2, 2' -dithiodibenzothiazole from crude pinosylvin sodium mother liquor and application thereof | 广东省生物医药技术研究所 | 2020-02-04 | — | — | CN | claimed |
| EP-1228074-B1 | METHOD OF PREPARING HIGHLY PURE CEFPODOXIME PROXETIL | HANMI PHARM IND CO LTD (KR) | 2005-06-15 | — | — | EP | claimed |
| US-6639068-B1 | Reacting cefpodoxime salt with 1-iodoethylisopropylcarbonate in presence of a crown ether | HANMI PHARM. CO., LTD. (KR) | 2003-10-28 | — | — | US | claimed |
| WO-2024127496-A1 | METALLO-β-LACTAMASE INHIBITOR AND USE THEREOF | 株式会社日本自然発酵 | 2024-06-20 | — | — | WO | disclosed |
| CN-110872322-B | Preparation method of cefaloside acetate monohydrate and intermediate thereof | 上海博志研新药物技术有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-113825543-A | Anthelmintic aza-benzothiophene and aza-benzofuran compounds | 勃林格殷格翰动物保健美国公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-113521314-A | HSP 90-Targeted inflammation and infection imaging and treatment | 纪念斯隆-凯特琳癌症中心 | 2021-10-22 | — | — | CN | disclosed |
| CN-107110869-B | HSP 90-Targeted inflammation and infection imaging and treatment | 纪念斯隆-凯特琳癌症中心 | 2021-08-10 | — | — | CN | disclosed |
| CN-110746373-A | Method for preparing 2, 2' -dithiodibenzothiazole from crude pinosylvin sodium mother liquor and application thereof | 广东省生物医药技术研究所 | 2020-02-04 | — | — | CN | disclosed |
| CN-110746373-A | Method for preparing 2, 2' -dithiodibenzothiazole from crude pinosylvin sodium mother liquor and application thereof | 广东省生物医药技术研究所 | 2020-02-04 | — | — | CN | disclosed |
| US-20100203567-A1 | ESBL Detection Kit and Method | THE LEWISHAM HOSPITAL NHS TRUST (GB) | 2010-08-12 | — | — | US | disclosed |
| CN-1981765-A | Medicament composition of cefpodoxime proxetil and cyclodextrin and preparation method thereof | RANBAXY LAB LTD (IN) | 2007-06-20 | — | — | CN | disclosed |
| CN-1981741-A | Method of improving biological utilization degree of precursor medicament using self-emulsification delivering system | RANBAXY LAB LTD (IN) | 2007-06-20 | — | — | CN | disclosed |
| CN-1977826-A | Method for increasing prodrug bioavailability using solid lipid nano granule | RANBAXY LAB LTD (IN) | 2007-06-13 | — | — | CN | disclosed |
| EP-1228074-B1 | METHOD OF PREPARING HIGHLY PURE CEFPODOXIME PROXETIL | HANMI PHARM IND CO LTD (KR) | 2005-06-15 | — | — | EP | disclosed |
| CN-1608624-A | Cefpoxime proxetil for clinical injection | BEIJING WEIKERUI INST OF MEDIC (CN) | 2005-04-27 | — | — | CN | disclosed |
| US-6639068-B1 | Reacting cefpodoxime salt with 1-iodoethylisopropylcarbonate in presence of a crown ether | HANMI PHARM. CO., LTD. (KR) | 2003-10-28 | — | — | US | disclosed |
| EP-1228074-A4 | METHOD OF PREPARING HIGHLY PURE CEFPODOXIME PROXETIL | HANMI PHARM IND CO LTD (KR) | 2003-02-26 | — | — | EP | disclosed |
| EP-1228074-A1 | METHOD OF PREPARING HIGHLY PURE CEFPODOXIME PROXETIL | Hanmi Pharm. Co., Ltd. (KR) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001034611-A1 | METHOD OF PREPARING HIGHLY PURE CEFPODOXIME PROXETIL | HANMI PHARM. CO., LTD. (KR) | 2001-05-17 | — | — | WO | disclosed |